We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The World Health Organization has added new treatments for hepatitis C to its essential medicines list, including Gilead Sciences’ Sovaldi and Harvoni, but says prices must come down before most people will be able to access them. Read More
The European Medicines Agency has granted orphan medicines designation to Hemispherx Biopharma Europe’s experimental Ebola treatment Ampligen. Read More
Vertex Pharmaceuticals’ Kalydeco/lumacaftor combination therapy may be in danger as regulators question whether it will provide significant improvements in lung function for most cystic fibrosis patients. Read More
Drugmakers can reduce the time it takes to obtain marketing authorization from EU regulators by about two months if they seek scientific advice and make suggested changes to their clinical development plans, a new analysis shows. Read More
Novartis’ Zykadia will soon be available as a second-line treatment for European patients with a specific type of non-small cell lung cancer, following European Medicines Agency approval late last week. Read More
The FDA Friday approved Bayer HealthCare’s Avelox for the treatment of pneumonic and septicemetic plague, under the animal efficacy rule. It also is approved to prevent plague in adults. Read More
The FDA has granted breakthrough therapy designation to AbbVie’s venetoclax to treat relapsed or refractory chronic lymphocytic leukemia in people with a certain genetic abnormality — paving the way for its speedy development and review. Read More